136 related articles for article (PubMed ID: 31980217)
1. Clinico-biological characteristics of patients with myelofibrosis: an analysis of 1,000 cases from the Spanish Registry of Myelofibrosis.
Pastor-Galán I; Hernández-Boluda JC; Correa JG; Alvarez-Larrán A; Ferrer-Marín F; Raya JM; Ayala R; Velez P; Pérez-Encinas M; Estrada N; García-Gutiérrez V; Fox ML; Payer A; Kerguelen A; Cuevas B; Durán MA; Ramírez MJ; Gómez-Casares MT; Mata-Vázquez MI; Mora E; Martínez-Valverde C; Arbelo E; Angona A; Magro E; Antelo ML; Somolinos N; Cervantes F;
Med Clin (Barc); 2020 Aug; 155(4):152-158. PubMed ID: 31980217
[TBL] [Abstract][Full Text] [Related]
2. Prognostic risk models for transplant decision-making in myelofibrosis.
Hernández-Boluda JC; Pereira A; Correa JG; Alvarez-Larrán A; Ferrer-Marín F; Raya JM; Martínez-López J; Velez P; Pérez-Encinas M; Estrada N; García-Gutiérrez V; Fox ML; Payer A; Kerguelen A; Cuevas B; Durán MA; Ramírez MJ; Gómez-Casares MT; Mata-Vázquez MI; Mora E; Gómez M; Cervantes F
Ann Hematol; 2018 May; 97(5):813-820. PubMed ID: 29396714
[TBL] [Abstract][Full Text] [Related]
3. Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.
Mitra D; Kaye JA; Piecoro LT; Brown J; Reith K; Mughal TI; Sarlis NJ
Cancer Med; 2013 Dec; 2(6):889-98. PubMed ID: 24403262
[TBL] [Abstract][Full Text] [Related]
4. The evolution and clinical relevance of prognostic classification systems in myelofibrosis.
Bose P; Verstovsek S
Cancer; 2016 Mar; 122(5):681-92. PubMed ID: 26717494
[TBL] [Abstract][Full Text] [Related]
5. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
6. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.
Hernández-Boluda JC; Pastor-Galán I; Arellano-Rodrigo E; Raya JM; Pérez-Encinas M; Ayala R; Ferrer-Marín F; Velez P; Mora E; Fox ML; Hernández-Rivas JM; Xicoy B; Mata-Vázquez MI; García-Fortes M; Pérez-López R; Angona A; Cuevas B; Senín A; Ramírez MJ; Ramírez-Payer A; Gómez-Casares MT; Martínez-Valverde C; Magro E; Steegmann JL; Durán MA; García-Hernández C; Gasior M; de Villambrosia SG; Alvarez-Larrán A; Pereira A;
Br J Haematol; 2022 Nov; 199(4):529-538. PubMed ID: 36089912
[TBL] [Abstract][Full Text] [Related]
7. Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2021 Jan; 96(1):145-162. PubMed ID: 33197049
[TBL] [Abstract][Full Text] [Related]
8. Primary Idiopathic Myelofibrosis: Clinico-Epidemiological Profile and Risk Stratification in Pakistani Patients.
Sultan S; Irfan SM
Asian Pac J Cancer Prev; 2015; 16(18):8629-31. PubMed ID: 26745128
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment.
Gergis U; Kuriakose E; Shore T; Mayer S; Mark T; Pearse R; Schuster M; Feldman E; Roboz G; Ritchie E; Scandura J; Wang H; Zhou XK; Silver RT; van Besien K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):297-303. PubMed ID: 27025789
[TBL] [Abstract][Full Text] [Related]
10. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
11. [Splanchnic vein thrombosis as a first manifestation of Primary myelofibrosis].
Campos-Cabrera G; Campos-Cabrera V; Campos-Cabrera S; Campos-Villagómez JL; Romero-González A
Gac Med Mex; 2017; 153(4):537-540. PubMed ID: 28991281
[TBL] [Abstract][Full Text] [Related]
12. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
[TBL] [Abstract][Full Text] [Related]
13. Survival and risk of vascular complications in myelofibrosis-A population-based study from the Swedish MPN group.
Lindgren M; Andréasson B; Samuelsson J; Pettersson H; Enblom-Larsson A; Ravn-Landtblom A; Scheding S; Bentham C; Ahlstrand E
Eur J Haematol; 2022 Oct; 109(4):336-342. PubMed ID: 35696444
[TBL] [Abstract][Full Text] [Related]
14. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution.
Cervantes F; Alvarez-Larrán A; Arellano-Rodrigo E; Granell M; Domingo A; Montserrat E
Leukemia; 2006 Jan; 20(1):55-60. PubMed ID: 16307011
[TBL] [Abstract][Full Text] [Related]
15. Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation.
Stein BL; Moliterno AR
JAMA; 2010 Jun; 303(24):2513-8. PubMed ID: 20571018
[TBL] [Abstract][Full Text] [Related]
16. Myelofibrosis patients in Belgium: disease characteristics.
Devos T; Zachée P; Bron D; Noens L; Droogenbroeck JV; Mineur P; Beguin Y; Berneman Z; Benghiat FS; Kentos A; Chatelain C; Demuynck H; Lemmens J; Eygen KV; Theunissen K; Trullemans F; Pierre P; Pluymers W; Knoops L
Acta Clin Belg; 2015 Apr; 70(2):105-11. PubMed ID: 25380026
[TBL] [Abstract][Full Text] [Related]
17. [Recent advances in the treatment of myelofibrosis].
Takenaka K
Rinsho Ketsueki; 2020; 61(9):1195-1204. PubMed ID: 33162516
[TBL] [Abstract][Full Text] [Related]
18. Myelofibrosis with myeloid metaplasia.
Barosi G
Hematol Oncol Clin North Am; 2003 Oct; 17(5):1211-26. PubMed ID: 14560783
[TBL] [Abstract][Full Text] [Related]
19. The forgotten myeloproliferative disorder: myeloid metaplasia.
Tefferi A
Oncologist; 2003; 8(3):225-31. PubMed ID: 12773744
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
